Medgenics consolidates corporate and R&D operations into new office facility
Medgenics has completed its move to a new facility on the Teradion Business Park in Misgav, Israel. The new facility brings together Medgenics' corporate operations with larger R&D laboratories on one site.
At the same time, the Company has more than doubled its scientific and engineering staff from four at Admission to ten now, in accordance with its plan and preparation for the Phase I/II clinical trial for EPODURE: its lead product in development to deliver a sustained therapeutic dose of erythropoietin (EPO) for the long-term treatment of anaemia. Subject to regulatory approval, EPODURE is on schedule to begin Phase I/II clinical trials in mid 2008 and preliminary data are anticipated from these trials within 3-5 months of trial commencement.
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
